Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
暂无分享,去创建一个
M. Mathews | S. Gopal | A. Savitz | I. Nuamah | Edward Kim | D. Hough | D. Najarian
[1] C. Correll,et al. Long-Acting Injections in Schizophrenia: a 3-Year Update on Randomized Controlled Trials Published January 2016–March 2019 , 2019, Current Psychiatry Reports.
[2] E. Plan,et al. Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia , 2017, Clinical Pharmacokinetics.
[3] B. Carpiniello,et al. Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia , 2016, Drug design, development and therapy.
[4] S. Gopal,et al. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3‐month formulation in patients with schizophrenia: A phase‐1, single‐dose, randomized, open‐label study , 2016, Journal of clinical pharmacology.
[5] W. Fleischhacker,et al. Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study , 2016, The international journal of neuropsychopharmacology.
[6] J. Stoddard,et al. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge. , 2015, Journal of managed care & specialty pharmacy.
[7] Yanning Liu,et al. Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial. , 2015, JAMA psychiatry.
[8] J. Lindenmayer,et al. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. , 2015, The Journal of clinical psychiatry.
[9] Chang Yoon Kim,et al. Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia , 2015, Neuropsychiatric disease and treatment.
[10] Yanning Liu,et al. Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies , 2013, Neuropsychiatric disease and treatment.
[11] R. McIntyre,et al. Treatment-emergent adverse events associated with atypical antipsychotics , 2012, Expert opinion on pharmacotherapy.
[12] S. Gopal,et al. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia , 2011, Journal of psychopharmacology.
[13] I. König,et al. Risk for antipsychotic-induced extrapyramidal symptoms: influence of family history and genetic susceptibility , 2011, Psychopharmacology.
[14] J. Lindenmayer,et al. A Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of 3 Doses of Paliperidone Palmitate in Adults With Acutely Exacerbated Schizophrenia , 2010, Journal of clinical psychopharmacology.
[15] S. Gopal,et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled study , 2010, Schizophrenia Research.
[16] E. Stip,et al. Substance abuse is associated with increased extrapyramidal symptoms in schizophrenia: A meta-analysis , 2009, Schizophrenia Research.
[17] A. Vermeulen,et al. Population Pharmacokinetics of Intramuscular Paliperidone Palmitate in Patients with Schizophrenia , 2009, Clinical pharmacokinetics.
[18] R. Lencer,et al. Family history of primary movement disorders as a predictor for neuroleptic-induced extrapyramidal symptoms. , 2004, The British journal of psychiatry : the journal of mental science.
[19] R. J. Leo,et al. Atypical Antipsychotic Use in the Treatment of Psychosis in Primary Care. , 2000, Primary care companion to the Journal of clinical psychiatry.
[20] T. Barnes,et al. Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics* , 1999, British Journal of Psychiatry.